Literature DB >> 3286503

Synthetic peptides of Shiga toxin B subunit induce antibodies which neutralize its biological activity.

I Harari1, A Donohue-Rolfe, G Keusch, R Arnon.   

Abstract

Shiga toxin B chain, the binding subunit of Shiga toxin, was recently purified; and the amino acid sequence of this 7,716-dalton polypeptide was determined (N.G. Seidah, A. Donohue-Rolfe, C. Lazure, F. Auclair, G. T. Keusch, and M. Chretien, J. Biol. Chem. 261:13928-13931, 1986). In the present study, synthetic peptides corresponding to three overlapping sequences from the N-terminal region of this subunit were prepared. The peptides synthesized consisted of residues 5 to 18, 13 to 26, and 7 to 26. This region coincides with the major peak of hydrophilicity and surface area residues predicted from a computer analysis. For the purpose of immunization, the peptides either were conjugated with a protein or synthetic carrier or were polymerized with glutaraldehyde. Antisera against these peptide derivatives raised in rabbits reacted not only with the respective homologous peptide but also to a comparable extent with the intact Shiga toxin. The anti-peptide antisera effectively neutralized the various biological activities of the Shiga toxin, namely, cytotoxicity to HeLa cells, enterotoxic activity (the fluid secretion into ligated ileal loops in rats), and neurotoxicity in mice. Furthermore, active immunization with the peptide conjugates was found to protect mice against the lethal effect of Shiga toxin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3286503      PMCID: PMC259446          DOI: 10.1128/iai.56.6.1618-1624.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Nucleotide sequence of the Shiga-like toxin genes of Escherichia coli.

Authors:  S B Calderwood; F Auclair; A Donohue-Rolfe; G T Keusch; J J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

2.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

3.  Serum enterotoxin-neutralizing antibody in human shigellosis.

Authors:  G T Keusch; M Jacewicz
Journal:  Nat New Biol       Date:  1973-01-03

4.  Shigellosis due to Shigella dysenteriae. 1. Relative importance of mucosal invasion versus toxin production in pathogenesis.

Authors:  P Gemski; A Takeuchi; O Washington; S B Formal
Journal:  J Infect Dis       Date:  1972-11       Impact factor: 5.226

5.  Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery.

Authors:  M M Levine; H L DuPont; S B Formal; R B Hornick; A Takeuchi; E J Gangarosa; M J Snyder; J P Libonati
Journal:  J Infect Dis       Date:  1973-03       Impact factor: 5.226

6.  Production, purification, and assay of cholera enterotoxin.

Authors:  R C Duhamel; P Talbot; G F Grady
Journal:  J Infect Dis       Date:  1970-05       Impact factor: 5.226

7.  Active antitoxic immunization by a diphtheria toxin synthetic oligopeptide.

Authors:  F Audibert; M Jolivet; L Chedid; J E Alouf; P Boquet; P Rivaille; O Siffert
Journal:  Nature       Date:  1981-02-12       Impact factor: 49.962

8.  Immunization with Shigella dysenteriae type 1: evaluation of antitoxic immunity in prevention of experimental disease in rhesus monkeys (Macaca mulatta).

Authors:  J McIver; G F Grady; S B Formal
Journal:  J Infect Dis       Date:  1977-09       Impact factor: 5.226

9.  Prediction of chain turns in globular proteins on a hydrophobic basis.

Authors:  G D Rose
Journal:  Nature       Date:  1978-04-13       Impact factor: 49.962

10.  Delayed hypersensitivity to fungal antigens in mice. II. Molecular classes in immunogenic RNA extracts that transfer delayed hypersensitivity.

Authors:  D Rifkind; J A Frey; E A Petersen; M Dinowitz
Journal:  J Infect Dis       Date:  1976-05       Impact factor: 5.226

View more
  18 in total

1.  Protection against Shiga toxin 1 challenge by immunization of mice with purified mutant Shiga toxin 1.

Authors:  Satoshi Ishikawa; Kazuyoshi Kawahara; Yutaka Kagami; Yasunori Isshiki; Aki Kaneko; Hidenori Matsui; Nobuhiko Okada; Hirofumi Danbara
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

2.  Characterization of Shiga-like toxin I B subunit purified from overproducing clones of the SLT-I B cistron.

Authors:  K Ramotar; B Boyd; G Tyrrell; J Gariepy; C Lingwood; J Brunton
Journal:  Biochem J       Date:  1990-12-15       Impact factor: 3.857

3.  Serological responses to the B subunit of Shiga-like toxin 1 and its peptide fragments indicate that the B subunit is a vaccine candidate to counter action of the toxin.

Authors:  B Boyd; S Richardson; J Gariepy
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

4.  Comparison of the western blot assay with the neutralizing-antibody and enzyme-linked immunosorbent assays for measuring antibody to verocytotoxin 1.

Authors:  D Reymond; M A Karmali; I Clarke; M Winkler; M Petric
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

5.  Identification of three amino acid residues in the B subunit of Shiga toxin and Shiga-like toxin type II that are essential for holotoxin activity.

Authors:  L P Perera; J E Samuel; R K Holmes; A D O'Brien
Journal:  J Bacteriol       Date:  1991-02       Impact factor: 3.490

6.  Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits.

Authors:  M Bielaszewska; I Clarke; M A Karmali; M Petric
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

7.  Functional analysis of the Shiga toxin and Shiga-like toxin type II variant binding subunits by using site-directed mutagenesis.

Authors:  M P Jackson; E A Wadolkowski; D L Weinstein; R K Holmes; A D O'Brien
Journal:  J Bacteriol       Date:  1990-02       Impact factor: 3.490

8.  Monoclonal antibody to Shiga toxin 2 which blocks receptor binding and neutralizes cytotoxicity.

Authors:  H Nakao; N Kiyokawa; J Fujimoto; S Yamasaki; T Takeda
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

Review 9.  Benchmarking B-cell epitope prediction for the design of peptide-based vaccines: problems and prospects.

Authors:  Salvador Eugenio C Caoili
Journal:  J Biomed Biotechnol       Date:  2010-03-30

10.  Immunogenicity of synthetic peptides of Haemophilus influenzae type b outer membrane protein P1.

Authors:  P Chong; Y P Yang; D Persaud; M Haer; B Tripet; E Tam; C Sia; M Klein
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.